Xuefeng Yu, president, co-founder and CEO of CanSino Biologics, discusses the company's collaboration projects with pharmaceutical companies, including AstraZeneca, as well as its first-half results. CanSino Biologics posted a net loss in the first half of 2022, mainly due to impairments related to the COVID-19 vaccine. But sales of commercial vaccines, such as the meningitis vaccine, exceeded expectations.
 
(MT Newswires)

Bloomberg videos